Tumor necrosis factor and interleukin-6 signaling complexes (TNF/IL-6)

The Tumor necrosis factor (TNF) and interleukin-6 (IL-6) signaling complexes are two distinct but functionally related molecular systems that drive systemic and local inflammation. TNF signaling is initiated by the binding of TNF-alpha to its receptors, TNFR1 and TNFR2, leading to the assembly of intracellular signaling complexes such as Complex I (which activates NF-kappaB and MAPK pathways for survival and inflammation) and Complex II (which can trigger apoptosis or necroptosis) (Source: UniProt P01375, P19438). IL-6 signaling involves the formation of a hexameric complex consisting of IL-6, the IL-6 receptor (IL-6R), and the signal-transducing subunit gp130, which primarily activates the JAK/STAT3 pathway to regulate the acute-phase response and immune cell differentiation (Source: UniProt P05231, P08887). These pathways are central to the pathogenesis of various autoimmune and inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and cytokine release syndrome (Source: PubMed 11007957). Therapeutic strategies target these complexes using monoclonal antibodies (e.g., adalimumab for TNF, tocilizumab for IL-6R) or soluble receptors (e.g., etanercept) to neutralize cytokine activity and alleviate disease symptoms. However, inhibiting these core immune pathways is associated with significant safety concerns, most notably an increased risk of serious infections and the potential reactivation of latent pathogens like Mycobacterium tuberculosis (Source: FDA Drug Labels).

Other names

TNF-alpha and IL-6 signaling pathwaysPro-inflammatory cytokine signaling complexesTNF-TNFR and IL-6-IL-6R-gp130 complexesTNF/IL-6 axis

Neutralization of soluble and membrane-bound TNF-alpha; competitive inhibition of IL-6 binding to IL-6R; blockade of gp130-mediated signal transduction; inhibition of NF-kappaB and JAK/STAT3 signaling cascades.